bioAffinity Technologies, Inc. Total Assets
bioAffinity Technologies, Inc. total assets. Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) holds total assets worth $10.96 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see bioAffinity Technologies, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of bioAffinity Technologies, Inc. (2019–2025)
Total assets of bioAffinity Technologies, Inc. from 2019 to 2025. This chart illustrates how bioAffinity Technologies, Inc.'s total assets have evolved over time, based on quarterly financial data. See bioAffinity Technologies, Inc. stock price for real-time trading data and today's change.
bioAffinity Technologies, Inc. - Asset Composition Analysis
bioAffinity Technologies, Inc. Total Assets Breakdown (December 2025)
bioAffinity Technologies, Inc. total assets breakdown as of December 2025. bioAffinity Technologies, Inc.'s total assets of $10.96 Million consist of 69.0% current assets and 31.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.8% |
| Accounts Receivable | $541.96K | 4.9% |
| Inventory | $53.55K | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $716.81K | 6.5% |
| Goodwill | $1.40 Million | 12.8% |
Asset Composition Trend (2019–2025)
This chart illustrates how bioAffinity Technologies, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BIAF net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: bioAffinity Technologies, Inc.'s current assets represent 69.0% of total assets in 2025, a decrease from 93.7% in 2019.
- Cash Position: Cash and equivalents constituted 58.8% of total assets in 2025, down from 87.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 12.8% of total assets.
bioAffinity Technologies, Inc. Competitors by Total Assets
Key competitors of bioAffinity Technologies, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.59 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
bioAffinity Technologies, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.60 | 0.87 | 0.01 |
| Quick Ratio | 2.58 | 0.86 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.66 Million | $-409.81K | $-11.00 Million |
bioAffinity Technologies, Inc. - Advanced Valuation Insights
This section examines the relationship between bioAffinity Technologies, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.41 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | 68.3% |
| Total Assets | $10.96 Million |
| Market Capitalization | $10.17 Million USD |
Valuation Analysis
Near Book Valuation: The market values bioAffinity Technologies, Inc.'s assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: bioAffinity Technologies, Inc.'s assets grew by 68.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for bioAffinity Technologies, Inc. (2019–2025)
The table below shows the annual total assets of bioAffinity Technologies, Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.96 Million | +68.27% |
| 2024-12-31 | $6.51 Million | -20.77% |
| 2023-12-31 | $8.22 Million | -32.51% |
| 2022-12-31 | $12.18 Million | +738.23% |
| 2021-12-31 | $1.45 Million | +898.12% |
| 2020-12-31 | $145.60K | -77.90% |
| 2019-12-31 | $658.81K | -- |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology t… Read more